Parkinson’s Disease – Landscape & Forecast – Disease Landscape & Forecast

Since 2015, eleven new brands have launched in the Parkinson’s disease (PD) therapy market (e.g., Inbrija [Acorda], Kynmobi [Sunovion], Ongentys [Neurocrine]), and several more are on the horizon, including AbbVie’s ABBV-951, Amneal’s IPX203, and Neuroderm’s ND-0612. As developers seek to carve out a clinical role for each of these products, they will introduce additional complexity to a complicated treatment algorithm. New brands have the potential to meaningfully increase the market value, but intensifying competition, coupled with patient and payer cost-sensitivity in a crowded and mostly generic market, creates a challenging launch environment. Generic options are available in every PD drug class, and brands entering these classes will struggle to compete without decisive clinical differentiation. A deep understanding of current and future market dynamics in PD will be critical for new and established players vying for a share of this increasingly competitive landscape.

Questions answered:

• What will be the clinical and commercial impact of emerging levodopa reformulations (i.e., ABBV-951, ND-0612, IPX203)? Will they experience rapid uptake and alter the PD treatment paradigm, or will access hurdles and/or physician resistance limit their use?
• How will neurologists differentiate between emerging adjunctive therapies for motor fluctuations (e.g., tavapadon vs. P2B001), and which will enjoy the greatest success in this highly generic market?
• How will neurologists adopt the new acute rescue therapies for “off” periods, and what unmet needs remain for other novel therapies targeting motor symptoms in PD?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 18 country-specific interviews with thought-leading neurologists; supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed and drug-treated prevalent cases of PD by country.

Emerging therapies: Phase II: 22 drugs; Phase III: 4 drugs; preregistration: 1 drug.

Market forecast features: 10-year, annualized, drug-level sales and patient shares of key PD therapies through 2031, segmented by brands / generics.

Key companies: AbbVie, Acadia Pharmaceuticals, Acorda Therapeutics, Adamas Pharmaceuticals, Amneal Pharmaceuticals, Cerevel Therapeutics, Eisai, Hisamitsu Pharmaceutical, Kyowa Kirin, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Newron Pharmaceuticals, NeuroDerm, Osmotica Pharmaceuticals, Pharma Two B, Sumitomo Dainippon Pharma, Sunovion, Supernus, Takeda, Teva, UCB, Zambon Pharma.

Key drugs: levodopa, amantadine, apomorphine, ABBV-951, Duodopa / Duopa, entacapone, Gocovri, Haruropi Tape, Inbrija, IPX203, Kynmobi, Lecigon, ND0612, Neupro, Nourianz, Nuplazid, Ongentys, Osmolex ER, pramipexole, P2B001, rasagiline, ropinirole, Rytary, selegiline, tavapadon, Trerief, Xadago.

Solution enhancement:

Disease Landscape & Forecast features continual updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.